Players competing at Wimbledon are set to be drug-tested more than ever before in the build-up to this year's championships as organisers focus resources on out-of-competition testing.
Scarred by a string of recent scandals, Wimbledon has announced its stepping up up the fight against doping but has revealed few details.
But in an email, the International Tennis Federation, which administers and part-funds the Tennis Anti-Doping Programme (TADP), said Wimbledon had discussed its plans with the ITF and will focus on out-of-competition testing.
The additional tests, which will be funded by Wimbledon, will be carried out by UK Anti-Doping (UKAD), the ITF said.
As a result, players competing at this year's championships could be tested out-of-competition in the run up to the grand slam event by UK Anti-Doping on behalf of Wimbledon, as well as being tested in and/or out-of-competition by the ITF.
Wimbledon said in a statement "as all anti-doping testing is carried out independently of the tournament organisers, we are not able to comment on the level of testing which will take place other than to say that we are fully supportive of a comprehensive In-Competition and Out-of-Competition testing programme."
Out-of-competition testing - which can be conducted at any time when a player is not actively involved in an event - is considered to be the best way to catch dopers, while blood testing has also become more prevalent in recent times.
In 2014, 1,439 of 3,529 tests were conducted out-of-competition, while in 2015 it was 2,256 out of 4,433.
In the past, the ITF has objected to requests from government-funded National Anti-Doping Organisations (NADOs) to test during grand slam events, seeing it as "a waste of resources" because of the duplication of effort.
The tennis anti-doping programme is run by the ITF and is jointly funded by the ATP Tour, WTA Tour, ITF and the four grand slams, including Wimbledon.
But a number of leading players, including Andy Murray, have called for vast increases to its funding, which is reportedly about $6 million per year, and for more transparency.
Maria Sharapova's admission last month that she had tested positive for the banned drug meldonium was the highest-profile case in a series of scandals that have affected the sport this year.
A report by the BBC and BuzzFeed in January, which suggested widespread match-fixing and a failure to investigate several implicated players, prompted the tennis authorities to launch an independent review into the Tennis Integrity Unit, which is due to release its findings by the end of the year.